Skip to main content
SpringerLink
Log in

Extra-intestinal Manifestations in Inflammatory Bowel Disease: Diagnosis and Management

  • Chapter
  • First Online:
Biomarkers in Inflammatory Bowel Diseases

  • 646 Accesses

Abstract

Inflammatory bowel disease is a systemic disorder that not only affects the gastrointestinal tract but can also be associated with extra-intestinal manifestations involving multiple organs. These most commonly include articular (axial and appendicular), dermatologic or ophthalmic involvement but can also more rarely include the renal and pulmonary systems. The clinical course can either mirror intestinal disease activity or be independent of it. Currently there is a need for effective biomarkers in this area as there are none available. While biomarkers are used for related rheumatological conditions, they are not effective as diagnostic or prognostic markers for extra-intestinal manifestations of IBD. Management of extra-intestinal manifestations may involve treating the underlying condition with some resolving as the bowel inflammation improves. Others may require treatment aimed specifically at the extra-intestinal manifestation. In refractory cases the best evidence tends to be for steroids and anti-TNF agents although other biologics and immunosuppressants may also play a role.

Dr. Ramesh Paramsothy and Dr. Peter Irving have no financial or potential competing interest or affiliation

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116–22.

    Article  CAS  Google Scholar 

  2. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110–9.

    Article  Google Scholar 

  3. Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Vavricka MP, Navarini AA, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794–800.

    Article  Google Scholar 

  4. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease: A prospective study of 792 patients. J Clin Gastroenterol. 1996;23(1):29–34.

    Article  CAS  Google Scholar 

  5. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7(4):235–41.

    Google Scholar 

  6. Patil SA, Cross RK. Update in the management of extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2013;15(3). (no pagination)(314).

    Google Scholar 

  7. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history. Gut. 1998;42(3):387–91.

    Article  CAS  Google Scholar 

  8. Trikudanathan G, Venkatesh PGK, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72(18):2333–49.

    Article  CAS  Google Scholar 

  9. Van Erp SJH, Verheul MK, Levarht EWN, Van Der Reijden JJ, Van Der Heijde D, Van Gaalen FA, et al. Short article: absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies. Eur J Gastroenterol Hepatol. 2017;29(3):345–8.

    Article  Google Scholar 

  10. Perez-Alamino R, Maldonado-Ficco H, Maldonado-Cocco JA. Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology. Clin Rheumatol. 2016;35(2):291–6.

    Article  Google Scholar 

  11. Colia R, Corrado A, Cantatore FP. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. Ann Med. 2016;48(8):577–85.

    Article  CAS  Google Scholar 

  12. Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MND. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6(2):65–77.

    Article  CAS  Google Scholar 

  13. Peyrin-Biroulet L, Van Assche G, Gomez-Ulloa D, Garcia-Alvarez L, Lara N, Black CM, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15(1):25–36.e27.

    Article  CAS  Google Scholar 

  14. Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47(4):485–93.

    Article  CAS  Google Scholar 

  15. Baeten D, De Keyser F, Mielants H, Veys EM. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2002;16(4):537–49.

    Article  Google Scholar 

  16. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–31.

    Article  CAS  Google Scholar 

  17. Baraliakos X, Braun J. Biologic therapies for spondyloarthritis: what is new. Curr Rheumatol Rep. 2012;14(5):422–7.

    Article  CAS  Google Scholar 

  18. Peluso R, Di Minno MND, Iervolino S, Manguso F, Tramontano G, Ambrosino P, et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol. 2013;2013. (no pagination)(631408).

    Google Scholar 

  19. Bonner GF, Fakhri A, Vennamanemi SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(6):751–7.

    Article  Google Scholar 

  20. Harbord M, Annese V, Vavricka SR, Allez M, Acosta MBD, Boberg KM, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohn’s Colitis. 2016;10(3):239–54.

    Article  Google Scholar 

  21. Hindryckx P, Novak G, Costanzo A, Danese S. Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11(3):203–14.

    CAS  PubMed  Google Scholar 

  22. Hendy PA, Bernardo D, Al-Hassi HO, Ding NS, Reddi D, Siaw YH, et al. Dendritic cell phenotype in crohn’s disease may correlate with disease severity and explain the high prevalence of cutaneous manifestations. Gut. 2015;64:A430–A1.

    Article  Google Scholar 

  23. Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine. 2008;87(5):281–93.

    Article  Google Scholar 

  24. Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2017;23(7):1174–81.

    Article  Google Scholar 

  25. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982–92.

    Article  Google Scholar 

  26. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 55(4):505–9.

    Article  CAS  Google Scholar 

  27. Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012;107(5):794–5.

    Article  CAS  Google Scholar 

  28. Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67(5):e237–8.

    Article  Google Scholar 

  29. Greb JE, Gottlieb AB, Goldminz AM. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther. 2016;29(6):482–3.

    Article  Google Scholar 

  30. Taleban S, Li D, Targan SR, Ippoliti A, Brant SR, Cho JH, et al. Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits. J Crohn’s Colitis. 2016;10(1):43–9.

    Article  Google Scholar 

  31. Mady R, Grover W, Butrus S. Ocular complications of inflammatory bowel disease. TheScientificWorldJOURNAL. 2015;2015:438402.

    Article  Google Scholar 

  32. Thomas AS, Lin P. Ocular manifestations of inflammatory bowel disease. Curr Opin Ophthalmol. 2016;27(6):552–60.

    Article  Google Scholar 

  33. Vavricka SR, Scharl M, Gubler M, Rogler G. Biologics for extraintestinal manifestations of IBD. Curr Drug Targets. 2014;15(11):1064–73.

    Article  CAS  Google Scholar 

  34. Akkoc N, Yarkan H, Kenar G, Khan MA. Ankylosing spondylitis: HLA-B 27-Positive versus HLA-B 27-Negative Disease. Curr Rheumatol Rep. 19(5):26.

    Google Scholar 

  35. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 10(2):135–9.

    Article  Google Scholar 

  36. Gueudry J, Thorne JE, Bansie R, Braun J, van Hagen PM, Bodaghi B. Biologic therapy for HLA-B27-associated ocular disorders. Ocul Immunol Inflamm. 2017;25(2):169–78.

    Article  CAS  Google Scholar 

  37. Bodaghi B, Bui Quoc E, Wechsler B, Tran THC, Cassoux N, Le Thi Huong D, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis. 2005;64(6):962–4.

    Article  CAS  Google Scholar 

  38. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696–701.

    Article  CAS  Google Scholar 

  39. Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol. 2002;97(2):377–81.

    Article  CAS  Google Scholar 

  40. Alrashid AI, Brown RD, Mihalov ML, Sekosan M, Pastika BJ, Venu RP. Crohn’s disease involving the lung: resolution with infliximab. Dig Dis Sci. 2001;46(8):1736–9.

    Article  CAS  Google Scholar 

  41. Regalia K, Shelton A, Berry G, Triadafilopoulos G, Cartwright CA. Pulmonary Crohn’s disease. Dig Dis Sci. 2017;62(1):64–7.

    Article  Google Scholar 

  42. McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002;89(9):835–41.

    Article  CAS  Google Scholar 

  43. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585–95.

    Article  CAS  Google Scholar 

  44. Greenstein AJ, Sachar DB, Panday AKN, Dikman SH, Meyers S, Heimann T, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine. 1992;71(5):261–70.

    Article  CAS  Google Scholar 

  45. Iizuka M, Konno S, Horie Y, Itou H, Shindo K, Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn’s disease [3]. Gut. 2006;55(5):744–5.

    Article  CAS  Google Scholar 

  46. Horie Y, Chiba M, Miura K, Iizuka M, Masamune O, Komatsuda A, et al. Crohn’s disease associated with renal amyloidosis successfully treated with an elemental diet. J Gastroenterol. 1997;32(5):663–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IBD Unit, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

    Ramesh Paramsothy & Peter Irving

Authors
  1. Ramesh Paramsothy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Irving
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Irving .

Editor information

Editors and Affiliations

  1. St Vincent’s Hospital, The University of Melbourne, Melbourne, VIC, Australia

    Nik Sheng Ding

  2. Austin Health, The University of Melbourne, Melbourne, VIC, Australia

    Peter De Cruz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Paramsothy, R., Irving, P. (2019). Extra-intestinal Manifestations in Inflammatory Bowel Disease: Diagnosis and Management. In: Sheng Ding, N., De Cruz, P. (eds) Biomarkers in Inflammatory Bowel Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-11446-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11446-6_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11445-9

  • Online ISBN: 978-3-030-11446-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation